用于确定抗精神病阈值和抗精神病治疗范围的氟哌利多临床试验。

Clinical trial of droperidol for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.

作者信息

Haase H J, Kaumeier S, Schwarz S, Gundel A, Linde O K, von Bomhard R H, Rauwolf E R, Scheel R, Seyfferth H, Stripf A, Stripf L

出版信息

Int Pharmacopsychiatry. 1980;15(1):74-80. doi: 10.1159/000468413.

DOI:10.1159/000468413

PMID:6993403

Abstract

In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured using Haase's graphopathological test) and the maximum dose were determined. The neuroleptic threshold dose was 18.5 mg/day (SD = 8.84), the maximum dose was 38.2 mg/day (SD = 4.6). With reference to the effectiveness good to very good results were obtained in 15 cases. Regarding side effects 10 patients complained of extrapyramidal disturbances. This was to be expected in view of the study design aiming at the determination of the maximum dose.

摘要

在一项涉及30名精神分裂症患者的开放性研究中，确定了抗精神病药物的阈剂量（使用哈泽氏组织病理学试验测量）和最大剂量。抗精神病药物的阈剂量为18.5毫克/天（标准差 = 8.84），最大剂量为38.2毫克/天（标准差 = 4.6）。在有效性方面，15例患者获得了良好至非常好的结果。关于副作用，10名患者抱怨有锥体外系障碍。鉴于该研究旨在确定最大剂量的设计，这是意料之中的。